Kata Kis-Toth

Kata Kis-Toth is an accomplished professional in the field of translational medicine, currently serving as Vice President of Translational Medicine at NextPoint Therapeutics, Inc. since April 2023. With a strong background in oncology and companion diagnostics, Kata previously held the position of Vice President and Head of Translational Sciences at Jounce Therapeutics, Inc. from September 2021 to April 2023, where responsibilities included developing immuno-oncology therapies tailored to patient populations. Prior experience includes roles as Director of Translational Sciences at Pandion Therapeutics, where Kata led efforts in biomarker activities for autoimmune diseases, and Director of Immunobiology at Kiniksa Pharmaceuticals, overseeing research in inflammatory diseases. Kata began a career in immunology as a Senior Scientist and Immunology Group Lead at Bioverativ, contributing to significant advancements in hemophilia therapies. Educational qualifications include a Ph.D. in Immunology from the University of Debrecen.